Completed PHASE2/PHASE3 INTERVENTIONAL 3-arm NCT00168103

Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks

Human Pasteurized C1 Esterase Inhibitor Concentrate (CE1145) in Subjects With Congenital C1-INH Deficiency and Acute Abdominal or Facial HAE Attacks

Sponsor: CSL Behring

Conditions Hereditary Angioedema

Interventions C1 Esterase Inhibitor Placebo

Updated 8 times since 2017 Last updated: Mar 11, 2015 Started: Jun 30, 2005 Primary completion: Oct 31, 2007 Completion: Dec 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Hereditary Angioedema, this trial is completed. The trial is conducted by CSL Behring and has accumulated 8 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2/PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Dec 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jan 2021 — Dec 2021 [monthly]

Completed PHASE2_PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2_PHASE3

First recorded

Jun 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CSL Behring

Data source: CSL Behring

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Bellingham, United States , Boston, United States , Brno, Czechia , Budapest, Hungary , Buenos Aires, Argentina , Chicago, United States , Cincinnati, United States , Dallas, United States , Edmonton, Canada and 24 more locations